The benchmark ASX 200 index is home to 200 of the largest listed companies on the Australian share market.
Among these companies are some true blue chip stars that could form the foundations for a winning portfolio.
But which ASX 200 shares could be top buys for investors today today? Let’s now take a look at three blue chip options for investors to consider buying:
Coles Group Ltd (ASX: COL)
The team at Bell Potter thinks that Coles could be an ASX 200 share to buy.
It is of course one of Australia’s largest supermarket operators. In addition, the company has a large liquor store network and joint ownership of the Flybuys loyalty program.
The broker likes the company due partly to its recent investment in automation and its online business. It believes that this “should help Coles maintain its market position.”
Bell Potter currently has a buy rating and $19.00 price target on the company’s shares.
CSL Limited (ASX: CSL)
Another ASX 200 share that analysts rate as a buy is CSL.
It is one of the world’s leading biotherapeutics companies with a collection of industry-leading therapies. This includes therapies such as Privigen, Hizentra, Idelvion, and Afstyla.
But CSL is never one to settle. Each year it reinvests in the region of 12% of its sales back into research and development (R&D) activities. Combined with its existing products and the rollout of its new plasma collection technology, the future looks bright for this ASX 200 blue chip star.
In light of this, it may not come as no surprise to learn that a large number of brokers are recommending CSL shares as a buy. One of those is Macquarie, which has an overweight rating and $330.00 price target on them.
ResMed Inc. (ASX: RMD)
A third ASX 200 share that could be a great addition to a portfolio is ResMed.
It is a medical device company with a focus on the sleep disorder market. This is a huge market, with an estimated one in five people suffering from a sleep disorder globally.
However, the majority of these people are not aware of their conditions. But with the awareness of sleep disorders and the health risks they pose increasing each year, ResMed looks well-placed to continue its solid growth long into the future.
Citi is bullish on ResMed and has a buy rating and $36.00 price target on its shares.
The post 3 of the best ASX 200 blue chip shares to buy now appeared first on The Motley Fool Australia.
Should you invest $1,000 in Coles Group Limited right now?
Before you buy Coles Group Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Coles Group Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
See The 5 Stocks
*Returns as of 5 May 2024
More reading
- 3 reasons to be positive on ASX 200 shares in FY25 (and 3 to be wary)
- Where Aussies are spending their money, and the ASX shares that could benefit
- 3 steps to take for a rich retirement with ASX shares
- Why Telstra and these excellent ASX dividend stocks could be buys
- Buying Coles shares? Here are key metrics you’ll want to know
Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Coles Group, Macquarie Group, and ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply